AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12657406 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (normal saline)
Number of subjects: 63
Study 10755072 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpublished rating scales
Number of subjects: 300
Study 10755072 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold-standard definition of treatment superiority with unpublished scales
Number of subjects: 300
Study 10755072 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological trials with unpublished scales
Number of subjects: 300
Study 9014667 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional carbon dioxide pneumoperitoneum
Number of subjects: 0
Study 9014667 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall lift method
Number of subjects: 0
Study 9014667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 1313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg o.d.
Number of subjects: 487
Study 1313717 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 500 mg o.d.
Number of subjects: 487
Study 1313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily for 15 days (tinea corporis/cruris) and 30 days (tinea pedis/manus).
Number of subjects: 487
Study 1313717 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 500 mg ultramicronized daily for 15 days (tinea corporis/cruris) and 30 days (tinea pedis/manus).
Number of subjects: 487
Study 1313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily.
Number of subjects: 487
Study 1313717 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 500 mg daily.
Number of subjects: 487
Study 3902268 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen + adriamycin + vinca alkaloid
Number of subjects: 183
Study 3902268 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin + vindesine
Number of subjects: 183
Study 3902268 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin + vincristine
Number of subjects: 183
Study 3902268 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin + vinca alkaloid
Number of subjects: 183
Study 31307095 — intervention group
Group type: EXPERIMENTAL
Intervention: Diced cartilage with I‐PRF
Number of subjects: 40
Study 31307095 — intervention group
Group type: COMPARATOR
Intervention: Diced cartilage without I‐PRF (control group)
Number of subjects: 40
Study 29607554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 76
Study 29607554 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 76
Study 29607554 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate ointment
Number of subjects: 76
Study 29607554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate ointment
Number of subjects: 76
Study 29607554 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus cream
Number of subjects: 76
Study 29607554 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone ointment
Number of subjects: 76
Study 29607554 — intervention group
Group type: COMPARATOR
Intervention: Vehicles
Number of subjects: 76
Study 26088405 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dimethylfumarate (DMF)
Number of subjects: 176
Study 25232107 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin modulation through pharmaceutical intervention
Number of subjects: 0
Study 25232107 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral evidence
Number of subjects: 0
Study 23364034 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized saline
Number of subjects: 114
Study 23364034 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 114
Study 20195284 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple activity-low TV cluster (women)
Number of subjects: 4682
Study 20195284 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance physical activity-low TV cluster (women)
Number of subjects: 4682
Study 20195284 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance physical activity cluster (men)
Number of subjects: 4682
Study 20195284 — intervention group
Group type: COMPARATOR
Intervention: Referent cluster (walking and gardening-low TV for men; walking and gardening-high TV for women)
Number of subjects: 4682
Study 17093981 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (max 1.8 mg/kg/day, daily) for 6-8 weeks
Number of subjects: 512
Study 17093981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 17093981 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 512
Study 16303728 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 143
Study 16303728 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 143
Study 12145241 — intervention group
Group type: EXPERIMENTAL
Intervention: NN2211 (1.25, 2.5, 5.0, 10.0, 12.5, 15.0, 17.5, and 20.0 microg/kg)
Number of subjects: 64
Study 12145241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 9631204 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnew Relationship Measure (ARM) completed by clients after every session (N = 1120)
Number of subjects: 95
Study 9631204 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnew Relationship Measure (ARM) completed by therapists after every session (N = 1120)
Number of subjects: 95
Study 9631204 — intervention group
Group type: EXPERIMENTAL
Intervention: Client initiative scale from the ARM
Number of subjects: 95
Study 8576747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile oxytocin administration (boluses every 8 minutes)
Number of subjects: 38
Study 8576747 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxytocin administration (conventional continuous intravenous infusion)
Number of subjects: 38
Study 2131793 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP (vincristine, melphalan, cyclophosphamide, and prednisone)
Number of subjects: 614
Study 2131793 — intervention group
Group type: COMPARATOR
Intervention: HBI (sequential hemibody radiation with vincristine and prednisone)
Number of subjects: 614
Study 773486 — intervention group
Group type: EXPERIMENTAL
Intervention: guanethidine and oxprenolol combination
Number of subjects: 13
Study 773486 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 13
Study 30312788 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyp sizing poster intervention for 33 endoscopists
Number of subjects: 38307
Study 30312788 — intervention group
Group type: COMPARATOR
Intervention: Control group for 29 endoscopists
Number of subjects: 38307
Study 28657141 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 24
Study 28657141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26341358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation intervention for 3 months, exercise 5 days a week using an iPad-based system, weekly video-conferencing with tele-therapists
Number of subjects: 100
Study 26341358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation intervention
Number of subjects: 100
Study 26341358 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 24257410 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help app based on acceptance and commitment therapy and mindfulness-based cognitive behavioural therapy
Number of subjects: 150
Study 24257410 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 150
Study 24257410 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help app
Number of subjects: 150
Study 21788542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules, 500 mg twice daily
Number of subjects: 221
Study 21788542 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX), 480 mg once daily
Number of subjects: 221
Study 19105776 — intervention group
Group type: EXPERIMENTAL
Intervention: Variall cementless hip system
Number of subjects: 333
Study 19105776 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene bearing
Number of subjects: 333
Study 16849391 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered HIV risk-reduction intervention
Number of subjects: 90
Study 16849391 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 90
Study 12639647 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation (FMS) using the Pulsegen device, B = 10 microT intensity, frequency of 10 Hz, worn day and night for 2 months.
Number of subjects: 55
Study 12639647 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no active treatment).
Number of subjects: 55
Study 10831274 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (400 mg/day) administered orally for 7 days prior to surgery
Number of subjects: 96
Study 9386863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/sqm day 1; fluorouracil 370 mg/sqm and L-folinic acid 100 mg/sqm days 1-3 administered every three weeks
Number of subjects: 46
Study 9386863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged 5FU/L-FA schedule (5 days)
Number of subjects: 46
Study 8465871 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine or phenelzine
Number of subjects: 0
Study 3001519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal alpha 2-interferon (5 X 10(6) IU)
Number of subjects: 448
Study 3001519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 30742482 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from spouse/partner or children
Number of subjects: 319
Study 30742482 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to promote ART adherence
Number of subjects: 319
Study 28130435 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-antagonist protocol
Number of subjects: 1050
Study 28130435 — intervention group
Group type: COMPARATOR
Intervention: GnRH-agonist protocol
Number of subjects: 1050
Study 27842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled intervention trial for pediatric weight management (EPOC study)
Number of subjects: 523
Study 27842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Completers of the intervention
Number of subjects: 523
Study 27842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Families with a more structured eating environment
Number of subjects: 523
Study 27842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analyses
Number of subjects: 523
Study 25016303 — intervention group
Group type: EXPERIMENTAL
Intervention: WHELD intervention (comprehensive staff training on person-centred care, activities, and psychotropic medication use)
Number of subjects: 80
Study 25016303 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 22743313 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-enriched diet (AED)
Number of subjects: 123
Study 22743313 — intervention group
Group type: COMPARATOR
Intervention: Nut-free diet (NFD)
Number of subjects: 123
Study 19618831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine without infusion (Group IV)
Number of subjects: 360
Study 19618831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine without infusion and restart infusion before propofol (Group VI)
Number of subjects: 360
Study 19618831 — intervention group
Group type: COMPARATOR
Intervention: Saline without infusion (Group III)
Number of subjects: 360
Study 19618831 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 360
Study 17888016 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported single-tooth replacements with different augmentation procedures
Number of subjects: 93
Study 17888016 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction questionnaire
Number of subjects: 93
Study 17888016 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between professional and patient ratings
Number of subjects: 93
Study 15727387 — intervention group
Group type: EXPERIMENTAL
Intervention: Home phototherapy (Bluelite Portable Light)
Number of subjects: 36
Study 15727387 — intervention group
Group type: COMPARATOR
Intervention: Hospital phototherapy (intense phototherapy with top and bottom light sources)
Number of subjects: 36
Study 15727387 — intervention group
Group type: EXPERIMENTAL
Intervention: Home phototherapy
Number of subjects: 36
Study 15727387 — intervention group
Group type: COMPARATOR
Intervention: Hospital phototherapy
Number of subjects: 36
Study 11816479 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR plus cisplatin
Number of subjects: 42
Study 11816479 — intervention group
Group type: COMPARATOR
Intervention: 5'‐DFUR alone
Number of subjects: 42
Study 10223775 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (200 mg carbamazepine tablet 3 times a day)
Number of subjects: 32
Study 10223775 — intervention group
Group type: COMPARATOR
Intervention: Reference product (200 mg carbamazepine tablet 3 times a day)
Number of subjects: 32
Study 8574859 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwaved spinach (150 g, 4.3 g dietary fibre)
Number of subjects: 10
Study 8574859 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwaved spinach (250 g, 7.2 g dietary fibre)
Number of subjects: 10
Study 8574859 — intervention group
Group type: COMPARATOR
Intervention: Control meal without spinach
Number of subjects: 10
Study 2239886 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid plus ursodeoxycholic acid (5 mm/kg of each)
Number of subjects: 120
Study 2239886 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (10 mm/kg) alone
Number of subjects: 120
Study 2239886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 120
Study 2239886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 120
Study 721788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazepam in divided doses
Number of subjects: 847
Study 721788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study 31302494 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pressure lumbosacral orthosis
Number of subjects: 48
Study 31302494 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure lumbosacral orthosis
Number of subjects: 48
Study 31302494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthosis)
Number of subjects: 48
Study 27757733 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg for 1 week, then 50 mg for 3 weeks, then eplerenone 50 mg for 1 month)
Number of subjects: 60
Study 27757733 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg for 1 week, then 50 mg for 3 weeks, then spironolactone 50 mg for 1 month)
Number of subjects: 60
Study 27757733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet for 1 week, then 2 tablets for 3 weeks, then spironolactone 50 mg for 1 month)
Number of subjects: 60
Study 27757733 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone and Eplerenone (both groups 1 and 2)
Number of subjects: 60
Study 26000578 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic diet
Number of subjects: 46
Study 26000578 — intervention group
Group type: COMPARATOR
Intervention: Non-neutropenic diet
Number of subjects: 46
Study 23890774 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action (PA) program
Number of subjects: 0
Study 23890774 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study 20737243 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg Cu/day (copper sulfate) for 2 months
Number of subjects: 0
Study 20737243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20737243 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper challenge with 1, 5, and 20 μM Cu-histidine for 20 hours
Number of subjects: 0
Study 18548559 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS-based technique
Number of subjects: 20
Study 18548559 — intervention group
Group type: COMPARATOR
Intervention: Regression analysis
Number of subjects: 20
Study 17691886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination cessation medications
Number of subjects: 470
Study 17691886 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling and combination pharmacotherapy
Number of subjects: 470
Study 14872400 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of bilateral movement training through mirror reflection
Number of subjects: 0
Study 11710825 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alpha2a, interleukin‐2, and 5‐fluorouracil
Number of subjects: 78
Study 11710825 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 78
Study 9385973 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured implants
Number of subjects: 25
Study 9385973 — intervention group
Group type: COMPARATOR
Intervention: Smooth implants
Number of subjects: 25
Study 7964949 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine-cisplatin (VP)
Number of subjects: 0
Study 7964949 — intervention group
Group type: COMPARATOR
Intervention: cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 0
Study 7964949 — intervention group
Group type: COMPARATOR
Intervention: best supportive care
Number of subjects: 0
Study 6690630 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐methyl‐2‐pyrrolidone (NMP)
Number of subjects: 0
Study 6690630 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone
Number of subjects: 0
Study 6690630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylformamide (DMF)
Number of subjects: 0
Study 6690630 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐pyrrolidone (2‐P)
Number of subjects: 0
Study 6690630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐ethyl‐2‐pyrrolidone (EP)
Number of subjects: 0
Study 6690630 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylene glycol (PG)
Number of subjects: 0
Study 6690630 — intervention group
Group type: EXPERIMENTAL
Intervention: N,N‐diethyl‐m‐toluamide (DEET)
Number of subjects: 0
Study 6690630 — intervention group
Group type: COMPARATOR
Intervention: DMI (dimethylisosorbide)
Number of subjects: 0
Study 31257613 — intervention group
Group type: COMPARATOR
Intervention: Camelina sativa oil (CSO) providing 10 g/day alpha-linolenic acid (ALA)
Number of subjects: 79
Study 31257613 — intervention group
Group type: COMPARATOR
Intervention: Fatty fish (four fish meals/week)
Number of subjects: 79
Study 31257613 — intervention group
Group type: COMPARATOR
Intervention: Lean fish (four fish meals/week)
Number of subjects: 79
Study 31257613 — intervention group
Group type: COMPARATOR
Intervention: Control diet with limited fish and ALA containing oil consumption
Number of subjects: 79
Study 29273470 — intervention group
Group type: EXPERIMENTAL
Intervention: IsaGenesis soft gel formulation
Number of subjects: 12
Study 29273470 — intervention group
Group type: COMPARATOR
Intervention: Product B powdered capsule
Number of subjects: 12
Study 26854478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) for 16 weeks
Number of subjects: 108
Study 26854478 — intervention group
Group type: COMPARATOR
Intervention: Collaborative Assessment and Management of Suicidality (CAMS) for up to 16 weeks
Number of subjects: 108
Study 26854478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 108
Study 26854478 — intervention group
Group type: COMPARATOR
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 108
Study 24219314 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal n-back task training (10 or 20 sessions)
Number of subjects: 0
Study 24219314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 22298802 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral bolus of 600,000 IU vitamin D₃
Number of subjects: 12
Study 22298802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 21146054 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 6 mg of hyperbaric or hypobaric bupivacaine (RQ group)
Number of subjects: 60
Study 21146054 — intervention group
Group type: COMPARATOR
Intervention: Combined sciatic-femoral nerve block with 800 mg of 1.6% lidocaine with epinephrine (CFI group)
Number of subjects: 60
Study 18020004 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapy for low-risk tumours
Number of subjects: 0
Study 18020004 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study 18020004 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy and hormonal therapy
Number of subjects: 0
Study 18020004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer risk assessment advancements
Number of subjects: 0
Study 16684855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg conjugated estrogens + 2.5 mg medroxyprogesterone acetate (n = 9)
Number of subjects: 33
Study 16684855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 33
Study 15252820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg daily)
Number of subjects: 353
Study 15252820 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-60 mg daily)
Number of subjects: 353
Study 15252820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 353
Study 15252820 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 353
Study 15252820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline and Paroxetine
Number of subjects: 353
Study 11119088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherens junctions and dense plaques in detrusor smooth muscle cells
Number of subjects: 13
Study 11119088 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry using labelled antibody to vinculin
Number of subjects: 13
Study 11119088 — intervention group
Group type: COMPARATOR
Intervention: Adherens junctions and dense plaques in control group
Number of subjects: 13
Study 11119088 — intervention group
Group type: COMPARATOR
Intervention: Comparison of junctions between patients and controls
Number of subjects: 13